New study checks if hypoparathyroidism drug passes into breast milk
NCT ID NCT07264634
First seen Jun 27, 2026 · Last updated Aug 07, 2026 · Updated 1 time
Summary
This study looks at how much of the drug palopegteriparatide (YORVIPATH) gets into breast milk. It involves 10 women with hypoparathyroidism who are already taking the drug and breastfeeding. Researchers will collect milk samples to measure drug levels, helping understand safety for nursing infants.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HYPOPARATHYROIDISM are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Ascendis Investigational Site
RECRUITINGMorgantown, West Virginia, 26508, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could a daily shot free teens from calcium pills?
- Weekly shot could free hypoparathyroidism patients from daily pills
- New daily shot could ease rare hormone disorder
- Glowing goggles could prevent calcium crash after thyroid surgery
- MRNA therapy offers hope for rare hormone disorder
- MRNA therapy takes on rare hormone disorder